TECENTRIQ (atezolizumab)

TECENTRIQ (atezolizumab)

OFFICE ADMINISTRATION

FDA Approved Indications:

• Treatment of locally advanced or metastatic urothelial carcinoma in patients who:
  • have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy, OR
  • are not eligible for cisplantin-containing chemotherapy
• Treatment of metastatic non-small cell lung cancer in patients who have disease progression during or following platinum-containing chemotherapy.  Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq

Patients must meet the following criteria for the indications above:

• Prescribed by an oncologist, AND
• Patient is at least 18 years of age, AND
• Chart note documentation confirms above diagnosis, AND
• For advance or metastic urothelial carcinoma: the patient has disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy, OR is not eligible for cisplatin-containing chemotherapy
• For metastic non-small cell lung cancer: the patient has disease progression during or following platinum-containing chemotherapy, AND patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to starting Tecentriq

Dosing:

• Administer 1200 mg as an IV infusion over 60 minutes every 3 weeks.

Approval:

• One year